Download PDF
Semin Respir Crit Care Med 2007; 28(6): 632-645
DOI: 10.1055/s-2007-996410
© Thieme Medical Publishers

Optimizing Therapy for Vancomycin-Resistant Enterococci (VRE)

Peter K. Linden1
  • 1Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Further Information

Publication History

Publication Date:
20 December 2007 (online)

    Permissions and Reprints

ABSTRACT

Enterococci are gram-positive, facultative bacteria with low intrinsic virulence but capable of causing a diverse variety of infections such as bacteremia with or without endocarditis, and intra-abdominal, wound, and genitourinary infection. During the past 2 decades the incidence of hospital-acquired enterococcal infection has significantly risen and is increasingly due to multidrug-resistant strains, primarily to the coacquisition of genetic determinants that encode for the stable expression of high-level β-lactam, aminoglycoside, and glycopeptide resistance.

Because enterococci constitute part of the normal colonizing flora, careful clinical interpretation of cultures that grow enterococci is paramount to avoid unnecessary and potentially deleterious antimicrobial therapy. Traditional antimicrobial treatment for ampicillin- and glycopeptide-susceptible enterococcal infection remains a penicillin-, ampicillin-, semisynthetic penicillin-based regimen, or vancomycin in a penicillin-intolerant individual. The need for a bactericidal combination with a cell-wall active agent combined with an aminoglycoside is most supported for native- or prosthetic valve endocarditis but is unproven for the majority of infections due to enterococci. The emergence of vancomycin-resistant enterococci prompted the clinical development of several novel and modified antimicrobial compounds approved for VRE infection (quinupristin-dalfopristin, linezolid) and several approved for non-VRE indications (daptomycin, tigecycline).

There is a paucity of comparative clinical trial data with these new agents, although linezolid, based upon its efficacy and tolerability, appears to be the cornerstone of current treatment approaches. Despite a relatively short period of clinical use, enterococcal resistance has now been described for quinupristin-dalfopristin and linezolid and more recently even for daptomycin and tigecycline. Moreover, the optimal treatment of endocarditis due to VRE strains is unknown because, with the exception of daptomycin, current treatment options only yield bacteriostasis. Nonantimicrobial measures to treat VRE infection, such as foreign body removal and percutaneous or surgical drainage of close-spaced infection, reduce both the need for and the duration of anti-enterococcal treatment and the emergence of resistance to the newer antimicrobials.

KEYWORDS

Enterococcus - vancomycin - linezolid - antimicrobial resistance - nosocomial infection

REFERENCES

  • 1 Centers for Disease Control and Prevention . National Nosocomial Infection Surveillance (NNIS) system: report, data summary from January 1992 through June 2003, issued August 2003.  Am J Infect Control. 2003;  31 481-498
    CrossrefPubMedGoogle Scholar
  • 2 Wisplinghoff H, Bischoff T, Tallent S M, Seiferd H, Wenzel R P, Edmond M B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.  Clin Infect Dis. 2004;  39 309-317
    CrossrefPubMedGoogle Scholar
  • 3 Moellering Jr R C. The Garrod Lecture. The Enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options.  J Antimicrob Chemother. 1991;  28 1-12
    CrossrefPubMedGoogle Scholar
  • 4 Murray B E. The life and times of the Enterococcus .  Clin Microbiol Rev. 1990;  3 46-65
    PubMedGoogle Scholar
  • 5 Hodges T L, Zighelboim-Daum S, Eliopoulos G M, Wennersten C, Moellering Jr R C. Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens.  Antimicrob Agents Chemother. 1992;  36 121-125
    PubMedGoogle Scholar
  • 6 Hamilton-Miller J M, Purves D. Enterococci and antifolate antibiotics.  Eur J Clin Microbiol. 1986;  5 391-394
    PubMedGoogle Scholar
  • 7 LeClercq R, Couvalin P. Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modification.  Antimicrob Agents Chemother. 1991;  35 1267-1272
    PubMedGoogle Scholar
  • 8 Lefort A, Mainardi J L, Tod M, Lotholary O. Antienterococcal antibiotics.  Med Clin North Am. 2000;  84 1471-1495
    CrossrefPubMedGoogle Scholar
  • 9 Rybkine T, Mainardi J L, Sougakoff W, Collatz E, Gutmann L. Penicillin- binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance.  J Infect Dis. 1998;  178 159-163
    PubMedGoogle Scholar
  • 10 Grayson M L, Eliopoulos G M, Wennersten C B et al.. Increasing resistance to ß-lactam antibiotics amongst clinical isolates of Enterococcus faecium: a 22-year review at one institution.  Antimicrob Agents Chemother. 1991;  35 2180-2184
    PubMedGoogle Scholar
  • 11 Horodniceanu T, Bougueleret L, El-Solh N, Bieth G, Delbos F. High level resistance to gentamicin in Streptococcus faecalis subsp. zymogenes .  Antimicrob Agents Chemother. 1979;  16 686-689
    PubMedGoogle Scholar
  • 12 Mederski-Samoraj B D, Murray B E. High level resistance to gentamicin in clinical isolates of enterococci.  J Infect Dis. 1983;  147 751-757
    PubMedGoogle Scholar
  • 13 Spiegel C A, Hucyke M. Endocarditis due to streptomycin-susceptible Enterococcus faecalis with high-level gentamicin resistance.  Arch Intern Med. 1989;  149 1873-1875
    CrossrefPubMedGoogle Scholar
  • 14 Eliopoulos G M. Aminoglycoside resistant enterococcal endocarditis.  Infect Dis Clin North Am. 1993;  7 117-133
    PubMedGoogle Scholar
  • 15 Leclercq R, Dutka-Malen S, Brisson-Noel A et al.. Resistance of enterococci to aminoglycosides and glycopeptides.  Clin Infect Dis. 1992;  15 495-501
    PubMedGoogle Scholar
  • 16 Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid mediated resistance to vancomycin and teicoplanin in Enterococcus faecium .  N Engl J Med. 1988;  319 157-161
    PubMedGoogle Scholar
  • 17 Centers for Disease Control and Prevention . Nosocomial enterococci resistant to vancomycin-United States 1989-1993.  MMWR Morb Mortal Wkly Rep.. 1993;  42 597-599
    PubMedGoogle Scholar
  • 18 Biedenbach D J, Moet G J, Jones R N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).  Diagn Microbiol Infect Dis. 2004;  50 59-69
    CrossrefPubMedGoogle Scholar
  • 19 Lai K K, Fontecchio S A, Kelly A L, Baker S, Melvin Z S. The changing epidemiology of vancomycin-resistant enterococci.  Infect Control Hosp Epidemiol. 2003;  24 264-268
    CrossrefPubMedGoogle Scholar
  • 20 Courvalin P. Vancomycin resistance in gram-positive cocci.  Clin Infect Dis. 2006;  42 S25-S34
    CrossrefPubMedGoogle Scholar
  • 21 Handwerger S, Skoble J. Identification of chromosomal mobile element conferring high-level vancomycin resistance in Enterococcus faecium .  Antimicrob Agents Chemother. 1995;  39 2446-2453
    PubMedGoogle Scholar
  • 22 Gold H S. Vancomycin resistant enterococci: mechanisms and clinical observations.  Clin Infect Dis. 2001;  33 210-219
    CrossrefPubMedGoogle Scholar
  • 23 Noble W C, Virani Z, Cree R G. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus .  FEMS Microbiol Lett. 1992;  72 195-198
    PubMedGoogle Scholar
  • 24 Chang S, Sievert D M, Hageman J C et al.. Infection with vancomycin- resistant Staphylococcus aureus containing the vanA resistance gene.  N Engl J Med. 2003;  348 1342-1347
    CrossrefPubMedGoogle Scholar
  • 25 Centers for Disease Control and Prevention (CDC) . Vancomycin-resistant Staphylococcus aureus-New York.  MMWR Morb Mortal Wkly Rep. 2005;  53 322-323
    PubMedGoogle Scholar
  • 26 Miller D, Urdaneta V, Weltman A. Vancomycin-resistant Staphylococcus aureus-Pennsylvania 2002.  MMWR Morb Mortal Wkly Rep. 2002;  51 902
    PubMedGoogle Scholar
  • 27 Sievert D M, Boulton M L, Stolzman G et al.. Staphylococcus aureus resistant to vancomycin-United States 2002.  MMWR Morb Mortal Wkly Rep. 2002;  51 565-567
    PubMedGoogle Scholar
  • 28 Whitener C J, Park S Y, Browne F A et al.. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.  Clin Infect Dis. 2004;  38 1049-1055
    CrossrefPubMedGoogle Scholar
  • 29 Donskey C J. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens.  Clin Infect Dis. 2004;  39 219-226
    CrossrefPubMedGoogle Scholar
  • 30 Beezhold D W, Slaughter S, Hayden M K et al.. Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia.  Clin Infect Dis. 1997;  24 704-706
    PubMedGoogle Scholar
  • 31 D'Agata E M, Gautam S, Green W K, Tang Y W. High rate of false- negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci.  Clin Infect Dis. 2002;  34 167-172
    CrossrefPubMedGoogle Scholar
  • 32 Weinstein J W, Tallapragada S, Farrel P, Dembry L M. Comparison of rectal and peri-rectal swabs for detection of colonization with vancomycin-resistant enterococci.  J Clin Microbiol. 1996;  34 210-212
    PubMedGoogle Scholar
  • 33 Montecalvo M A, Lencastre H, Carraher M et al.. Natural history of colonization with vancomycin-resistant Enterococcus faecium .  Infect Control Hosp Epidemiol. 1995;  16 680-685
    PubMedGoogle Scholar
  • 34 Baden L R, Thiemke W, Skolnik A et al.. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of “clearance”.  Clin Infect Dis. 2001;  33 1654-1660
    PubMedGoogle Scholar
  • 35 Roghmann M C, Aquiyumi S, Schwalbe R, Morris Jr J G. Natural history of colonization with vancomycin-resistant Enterococcus faecium .  Infect Control Hosp Epidemiol. 1997;  18 679-680
    PubMedGoogle Scholar
  • 36 Tornieporth N G, Roberts R B, Hafner J J, Riley L W. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case and control patients.  Clin Infect Dis. 1996;  23 767-772
    PubMedGoogle Scholar
  • 37 Bonten M J, Hayden M K, Nathan C et al.. Epidemiology of colonization of patients and environment with vancomycin-resistant enterococci.  Lancet. 1996;  348 1615-1619
    CrossrefPubMedGoogle Scholar
  • 38 Morris J G, Shay D K, Hebden J N et al.. Enterococci resistant to multiple antimicrobial agents including vancomycin, establishment of endemicity in a university medical center.  Ann Intern Med. 1995;  123 250-259
    PubMedGoogle Scholar
  • 39 Warren D K, Kollef M H, Seiler S M, Fridkin S K, Fraser V J. The epidemiology of vancomycin-resistant Enterococcus in a medical intensive care unit.  Infect Control Hosp Epidemiol. 2003;  24 257-263
    CrossrefPubMedGoogle Scholar
  • 40 Donskey C J, Chowdhry T, Hecker M et al.. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.  N Engl J Med. 2000;  343 1925-1932
    CrossrefPubMedGoogle Scholar
  • 41 Bonten M J, Slaughter S, Ambergen A W et al.. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection control variable.  Arch Intern Med. 1998;  158 1127-1132
    PubMedGoogle Scholar
  • 42 Linden P. Can enterococcal infections initiate sepsis syndrome?.  Curr Infect Dis Rep. 2003;  5 372-378
    CrossrefPubMedGoogle Scholar
  • 43 Kollef M H, Sherman G, Ward S, Fraser V J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.  Chest. 1999;  115 462-472
    CrossrefPubMedGoogle Scholar
  • 44 Kumar A, Robert D, Wood K E et al.. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.  Crit Care Med. 2006;  34 1589-1596
    CrossrefPubMedGoogle Scholar
  • 45 Ibrahim E H, Sherman G, Ward S, Fraser V J, Kollef M H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.  Chest. 2000;  118 146-155
    CrossrefPubMedGoogle Scholar
  • 46 Quale J, Landman D, Atwood E et al.. Experience with a hospital-wide outbreak of vancomycin-resistant enterococci.  Am J Infect Control. 1996;  24 372-379
    CrossrefPubMedGoogle Scholar
  • 47 Lai K K. Treatment of vancomycin resistant Enterococcus faecium infections.  Arch Intern Med. 1996;  156 2579-2584
    CrossrefPubMedGoogle Scholar
  • 48 Pankey G A, Sabath L D. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections.  Clin Infect Dis. 2004;  38 864-870
    CrossrefPubMedGoogle Scholar
  • 49 Finberg R W, Moellering R C, Tally F P et al.. The importance of bactericidal drugs, future directions in infectious diseases.  Clin Infect Dis. 2004;  39 1314-1320
    CrossrefPubMedGoogle Scholar
  • 50 Tsigrelis C, Singh K V, Coutinho T D, Murray B E, Baddour L M. Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors.  J Clin Microbiol. 2007;  45 631-635
    PubMedGoogle Scholar
  • 51 Mekonen E T, Noskin G A, Hacek D M, Peterson L R. Successful treatment of persistent bacteremia due to vancomycin resistant ampicillin resistant Enterococcus faecium .  Microb Drug Resist. 1995;  1 249-253
    PubMedGoogle Scholar
  • 52 Dodge R A, Daly J S, Davaro R, Glew R H. High-dose ampicillin plus streptomycin for treatment of a patient with severe infection due to multi-drug resistant enterococci.  Clin Infect Dis. 1997;  25 1269-1270
    PubMedGoogle Scholar
  • 53 Murray B E. Vancomycin-resistant enterococcal infections.  N Engl J Med. 2000;  342 710-721
    CrossrefPubMedGoogle Scholar
  • 54 Lautenbach E, Schuster M G, Biler W B et al.. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus .  Clin Infect Dis. 1998;  27 1259-1265
    PubMedGoogle Scholar
  • 55 Gould C V, Fishman N O, Nakamkin N I, Lautenbach E. Chloramphenicol resistance in vancomycin resistant enterococcal bacteremia: impact of prior fluoroquinolone use.  Infect Control Hosp Epidemiol. 2004;  25 138-145
    CrossrefPubMedGoogle Scholar
  • 56 Howe R A, Robson M, Oakhill A et al.. Successful use of tetracycline as therapy of an immunocompromised patient with septicemia caused by a vancomycin-resistant Enterococcus .  J Antimicrob Chemother. 1997;  40 144-145
    CrossrefPubMedGoogle Scholar
  • 57 Linden P K, Pasculle A W, Manez R et al.. Utilization of novobiocin and ciprofloxacin for the treatment of serious infection due to vancomycin-resistant Enterococcus faecium. In: Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. Abstract 1027. Washington, DC; American Society for Microbiology 1993: 307
    Google Scholar
  • 58 Montecalvo M A, Horowitz H, Wormser G P et al.. Effect of novobiocin containing antimicrobial regimens on infection and colonization with vancomycin resistant Enterococcus faecium. .  Antimicrob Agents Chemother. 1995;  39 794
    PubMedGoogle Scholar
  • 59 Taylor S E, Paterson D L, Yu V L. Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium .  Eur J Clin Microbiol Infect Dis. 1998;  17 798-800
    CrossrefPubMedGoogle Scholar
  • 60 Schmit J L. Efficacy of teicoplanin for enterococcal infections: 63 cases and review.  Clin Infect Dis. 1992;  15 302-306
    PubMedGoogle Scholar
  • 61 Aslangul E, Baptista M, Fantin B et al.. Selection of glycopeptide-resistant mutants of VanB type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis.  J Infect Dis. 1997;  175 598-605
    PubMedGoogle Scholar
  • 62 Hayden M K, Trenholme G M, Schultz J E et al.. In vivo development of teicoplanin resistance in a VanB Enterococcus faecalis .  J Infect Dis. 1993;  167 1224-1227
    CrossrefPubMedGoogle Scholar
  • 63 Zhanel G G, Hoban D J, Karlowsky J A. Nitrofurantoin is active against vancomycin-resistant enterococci.  Antimicrob Agents Chemother. 2001;  45 324-326
    CrossrefPubMedGoogle Scholar
  • 64 Linden P, Coley K, Kusne S. Bacteriologic efficacy of nitrofurantoin for the treatment of urinary tract infection due to vancomycin-resistant Enterococcus faecium .  Clin Infect Dis. 1999;  29 999
    PubMedGoogle Scholar
  • 65 Cocito C, DiGiambattista M, Nyssen E, Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics.  J Antimicrob Chemother. 2007;  39(Suppl A) 7-13
    PubMedGoogle Scholar
  • 66 Hershberger E, Donabedian S, Konstantinou K, Zervos M J. Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology.  Clin Infect Dis. 2004;  38 92-98
    CrossrefPubMedGoogle Scholar
  • 67 Moellering R C, Linden P K, Reinhardt J et al.. The efficacy and safety of quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium .  J Antimicrob Chemother. 1999;  44 251-271
    CrossrefPubMedGoogle Scholar
  • 68 Linden P K, Moellering R C, Wood C A et al.. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin.  Clin Infect Dis. 2001;  33 1816-1823
    CrossrefPubMedGoogle Scholar
  • 69 Brown J, Freeman B B. Combining quinupristin/dalfopristin with other agents for resistant infections.  Ann Pharmacother. 2004;  38 677-685
    CrossrefPubMedGoogle Scholar
  • 70 Bethea J A, Walko C M, Targos P A. Treatment of vancomycin-resistant Enterococcus with quinupristin/dalfopristin and high dose-ampicillin.  Ann Pharmacother. 2004;  38 989-91
    CrossrefPubMedGoogle Scholar
  • 71 Thompson R L, Lavin B, Talbot G H. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin.  South Med J. 2003;  96 818-820
    CrossrefPubMedGoogle Scholar
  • 72 Raad I, Hachem R, Hanna H et al.. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.  Antimicrob Agents Chemother. 2001;  45 3202-3204
    CrossrefPubMedGoogle Scholar
  • 73 Olsen K M, Rebuck J A, Rupp M E. Arthralgias and myalgias related to quinupristin-dalfopristin administration.  Clin Infect Dis. 2001;  32 e83-e86
    CrossrefPubMedGoogle Scholar
  • 74 Werner G, Klare I, Spencker F B, Witte W. Intra-hospital dissemination of quinupristin-dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital.  J Antimicrob Chemother. 2003;  52 113-115
    CrossrefPubMedGoogle Scholar
  • 75 Donabedian S M, Perri M B, Vager D et al.. Quinupristin-dalfopristin resistance in Enterococcus faecium isolates from humans, farm animals, and grocery store meat in the United States.  J Clin Microbiol. 2006;  44 3361-3365
    CrossrefPubMedGoogle Scholar
  • 76 Moellering R C. Linezolid: the first oxazolidinone antimicrobial.  Ann Intern Med. 2003;  138 135-142
    PubMedGoogle Scholar
  • 77 Pharmacia and Upjohn .Linezolid for the Treatment of Vancomycin Resistant Enterococcal Infections: A Double-Blind Trial Comparing 600 mg Linezolid Every 12 Hours with 200 mg Linezolid Every 12 Hours (study report M/1260/0054A). Peapack, NJ; Pharmacia Upjohn 1999
    Google Scholar
  • 78 Birmingham M C, Raynes C R, Meagher A K, Flavin S M, Batts D H, Schentag J J. Linezolid for the treatment of multidrug-resistant gram-positive infections: experience from a compassionate use program.  Clin Infect Dis. 2003;  36 159-168
    CrossrefPubMedGoogle Scholar
  • 79 Stevens M P, Edmond M B. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature.  Clin Infect Dis. 2005;  41 1134-1142
    CrossrefPubMedGoogle Scholar
  • 80 Archuleta S, Murphy B, Keller M J. Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection.  Transpl Infect Dis. 2004;  6 117-119
    CrossrefPubMedGoogle Scholar
  • 81 Babcock H M, Ritchie D J, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.  Clin Infect Dis. 2001;  32 1373-1375
    CrossrefPubMedGoogle Scholar
  • 82 Zimmer S M, Caliendo A M, Thigpen M C, Somani J. Failure of linezolid treatment for enterococcal endocarditis.  Clin Infect Dis. 2003;  37 e29-e30
    CrossrefPubMedGoogle Scholar
  • 83 Tsigrelis C, Singh K V, Coutinho T D, Murray B E, Baddour L M. Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors.  J Clin Microbiol. 2007;  45 631-635
    PubMedGoogle Scholar
  • 84 Gonzales R D, Schreckenberger P C, Graham M B et al.. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.  Lancet. 2001;  357 1179
    CrossrefPubMedGoogle Scholar
  • 85 Seedat J, Zick G, Klare I et al.. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.  Antimicrob Agents Chemother. 2006;  50 4217-4219
    CrossrefPubMedGoogle Scholar
  • 86 Marra A R, Major Y, Edmond M D. Central venous catheter colonization by linezolid-resistant, vancomycin-susceptible Enterococcus faecalis .  J Clin Microbiol. 2006;  44 1915-1916
    CrossrefPubMedGoogle Scholar
  • 87 Rahim S, Pillai S K, Gold H S, Venkataraman L, Inglima K, Press R A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid.  Clin Infect Dis. 2003;  36 E146-148
    CrossrefPubMedGoogle Scholar
  • 88 Swaney S M, Shinabarger D L, Schaadt R D, Bock J H, Slightom J L, Zurenko G E. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA [abstract C-104]. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego. Washington, DC; American Society for Microbiology 1998: 98-99
    Google Scholar
  • 89 Herrero I A, Issa N C, Patel R. Nosocomial spread of linezolid-resistant vancomycin-resistant Enterococcus faecium .  N Engl J Med. 2002;  346 867-869
    PubMedGoogle Scholar
  • 90 Marshall S H, Donskey C J, Hutton-Thomas R, Salata R A, Rice L B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis .  Antimicrob Agents Chemother. 2002;  46 3334-3336
    CrossrefPubMedGoogle Scholar
  • 91 Pai M P, Rodvold K A, Schreckenbefger P C, Gonezales R D, Petrolatti J M, Quinn J P. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium .  Clin Infect Dis. 2002;  35 1269-1272
    CrossrefPubMedGoogle Scholar
  • 92 Green S L, Maddox J C, Huttenbach E D. Linezolid and reversible myelosuppression.  JAMA. 2001;  285 1291
    CrossrefPubMedGoogle Scholar
  • 93 Halpern M. Linezolid-induced pancytopenia.  Clin Infect Dis. 2002;  35 347-348
    PubMedGoogle Scholar
  • 94 Wigen C L, Goetz M B. Serotonin syndrome and linezolid.  Clin Infect Dis. 2002;  34 1651-1652
    CrossrefPubMedGoogle Scholar
  • 95 Saijo T, Hayashi K, Yamada H, Wakakura M. Linezolid-induced optic neuropathy.  Am J Ophthalmol. 2005;  139 1114-1116
    CrossrefPubMedGoogle Scholar
  • 96 Bressler A M, Zimmer S M, Gilmore J L, Somani J. Peripheral neuropathy associated with prolonged use of linezolid.  Lancet Infect Dis. 2004;  4 528-531
    CrossrefPubMedGoogle Scholar
  • 97 Apodaca A A, Rakita R M. Linezolid-induced lactic acidosis.  N Engl J Med. 2003;  348 86-87
    CrossrefPubMedGoogle Scholar
  • 98 Carpenter C F, Chambers H F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.  Clin Infect Dis. 2004;  38 994-1000
    CrossrefPubMedGoogle Scholar
  • 99 Pfaller M A, Sader H S, Jones R N. Evaluation of the in vitro activity of daptomycin against 19615 clinical isolates of gram positive cocci collected in North American hospitals (2002-2005).  Diagn Microbiol Infect Dis  2007;  57 459-465
    PubMedGoogle Scholar
  • 100 Jorgensen J H, Crawford S A, Kelly C C, Patterson J E. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods.  Antimicrob Agents Chemother. 2003;  47 3760-3763
    CrossrefPubMedGoogle Scholar
  • 101 Anastasiou D M, Thorne G M, Luperchio S A, Alder J D. In vitro activity of daptomycin against clinical isolates with reduced susceptibility to linezolid and quinupristin/dalfopristin.  Int J Antimicrob Agents. 2006;  28 385-388
    PubMedGoogle Scholar
  • 102 Poutsiaka D D, Skiffingeron S, Miller K B, Hadley S, Snydman D R. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients.  J Infect. 2007;  54 567-571
    CrossrefPubMedGoogle Scholar
  • 103 Segreti J A, Crank C W, Finney M S. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.  Pharmacotherapy. 2006;  26 347-352
    CrossrefPubMedGoogle Scholar
  • 104 Long J K, Choueiri T K, Hall G S, Avery R K, Sekeres M A. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia.  Mayop Clin Proc. 2005;  80 1215-1216
    PubMedGoogle Scholar
  • 105 Munoz-Price L S, Lolans K, Quinn J P. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection.  Clin Infect Dis. 2005;  41 565-566
    CrossrefPubMedGoogle Scholar
  • 106 Lewis II J S, Owens A, Cadena J et al.. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.  Antimicrob Agents Chemother. 2005;  49 1664-1665
    CrossrefPubMedGoogle Scholar
  • 107 Green M R, Anasetti C, Sandin R L, Rolfe N E, Greene J N. Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans .  J Oncol Pharm Pract. 2006;  12 179-181
    PubMedGoogle Scholar
  • 108 Stein G E, Craig W A. Tigecycline: a critical analysis.  Clin Infect Dis. 2006;  43 518-524
    CrossrefPubMedGoogle Scholar
  • 109 Sader H S, Jones R N, Stilwell M G, Dowzicky M J, Fritsche T R. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.  Diagn Microbiol Infect Dis. 2005;  52 181-186
    CrossrefPubMedGoogle Scholar
  • 110 Streit J M, Sader H S, Fritsche T R, Jones R N. Dalbabancin activity against selected populations of antimicrobial resistant gram-positive pathogens.  Diagn Microbiol Infect Dis. 2005;  53 307-310
    CrossrefPubMedGoogle Scholar
  • 111 Barrett J F. Recent developments in glycopeptide antibacterials.  Curr Opin Investig Drugs. 2005;  6 781-790
    PubMedGoogle Scholar
  • 112 Baltch A L, Smith R P, Ritz W J, Bopp L H. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY-333328 and ampicillin used singly and in combination against Enterococcus faecium .  Antimicrob Agents Chemother. 1998;  42 2564-2568
    PubMedGoogle Scholar
  • 113 Stryjewski M E, Chu V H, O'Riordan W D et al.. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 Study.  Antimicrob Agents Chemother. 2006;  50 862-867
    CrossrefPubMedGoogle Scholar
  • 114 Poulakou G, Giamarellou H. Investigational treatments for postoperative surgical site infections.  Expert Opin Investig Drugs. 2007;  16 137-155
    CrossrefPubMedGoogle Scholar

Peter K LindenM.D. 

Department of Critical Care Medicine, University of Pittsburgh Medical Center

602 A Scaife Hall, 3550 Terrace St., Pittsburgh, PA 15261

Email: lindenpk@ccm.upmc.edu

      >